Journal articlePreclinical
Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
Neurobiology of disease, 2014 Nov. Kazim SF, Blanchard J, Dai CL and 4 others.
Study type
Journal article
Subjects
Animal / preclinical (no Humans MeSH term)
Journal
Neurobiology of disease
Published
2014 Nov
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Administration, OralAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsAntipsychotic AgentsBlood-Testis BarrierBrainCells, CulturedCiliary Neurotrophic FactorDisease Models, AnimalEnzyme InhibitorsFemale
Other papers on P21
Review · 2022
Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound
Journal article · 2021Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction
Journal article · 2017Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page